Mihăilescu R, Vitzu M, Brestoiu S
Cantacuzino Institute, Bucharest, Romania.
Arch Roum Pathol Exp Microbiol. 1990 Oct-Dec;49(4):315-21.
192 patients, 72 women and 120 men, aged 18-75, presenting genital herpes, were followed. Among these, 122 formed the test batch, exclusively with Antiherpin, and 70 represented the control batch, treated with other therapeutic preparations. Antiherpin was administered by percutaneous route, by scarification. The following results were obtained: in the test batch 68.02% recoveries, 30.33% improvements and 1.64% statu quo; in the control batch no recoveries were recorded: only 60% statu quo but also 40% aggravations. However, after Antiherpin treatment beginning, even in this batch favourable results were obtained: in statu quo category, 66.7% recoveries, 30.9% improvements were obtained, 2.4% being not influenced by the treatment; in aggravation category 50% recoveries, 42.9% improvements were obtained, 7.1% maintaining their statu quo. During Antiherpin treatment, no case of adverse reaction was recorded, the preparation being very well tolerated by the organism. The above mentioned results prove Antiherpin efficacy in the treatment and prevention of genital herpes, even in the case of the patients previously being administered another treatment type.
对192例年龄在18 - 75岁、患有生殖器疱疹的患者进行了跟踪研究，其中72例为女性，120例为男性。在这些患者中，122例组成试验组，仅使用抗疱疹素进行治疗，70例作为对照组，使用其他治疗制剂进行治疗。抗疱疹素通过划痕经皮给药。得到以下结果：试验组的治愈率为68.02%，好转率为30.33%，病情无变化率为1.64%；对照组无治愈病例：病情无变化率仅为60%，但病情加重率为40%。然而，在开始使用抗疱疹素治疗后，即使在该组中也取得了良好的效果：在病情无变化类别中，治愈率为66.7%，好转率为30.9%，2.4%不受治疗影响；在病情加重类别中，治愈率为50%，好转率为42.9%，7.1%病情维持不变。在抗疱疹素治疗期间，未记录到不良反应病例，该制剂在机体中耐受性良好。上述结果证明抗疱疹素在治疗和预防生殖器疱疹方面具有疗效，即使对于先前接受过其他治疗类型的患者也是如此。
